clinical trial · NCT07503210
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Novo Nordisk A/S·phase3·recruiting·n = 600
ObesityNNC0487-0111Placebo (matched to NNC0487-0111)
brief summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
started
Apr 21, 2026
primary completion
Jun 6, 2028
completion
Jul 4, 2028
last updated
May 19, 2026
official title
Efficacy and Safety of NNC0487-0111 s.c. Once Weekly in Participants With Obesity Who Have Reached Target Dose During run-in Period (AMAZE 12)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol